Request Demo

Last update 08 May 2025

Epididymitis

Last update 08 May 2025

Basic Info

Synonyms

EPIDIDYMITIS, Epididymis inflamed, Epididymitides

+ [15]

Introduction

Inflammation of the EPIDIDYMIS. Its clinical features include enlarged epididymis, a swollen SCROTUM; PAIN; PYURIA; and FEVER. It is usually related to infections in the URINARY TRACT, which likely spread to the EPIDIDYMIS through either the VAS DEFERENS or the lymphatics of the SPERMATIC CORD.

Drugs associated with Epididymitis

Levofloxacin

Target

Bacterial DNA gyrase x Bacterial top IV

Mechanism

Bacterial DNA gyrase inhibitors [+1]

Active Org.

CHIESI Farmaceutici SpA [+5]

Originator Org.

Johnson & Johnson

Active Indication

Otitis Externa [+31]

Inactive Indication

Abscess [+35]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date20 Dec 1996

Minocycline Hydrochloride

Target

30S subunit

Mechanism

30S subunit inhibitors

Active Org.

Pfizer Inc. [+9]

Originator Org.

Pfizer Inc.

Active Indication

Rosacea [+38]

Inactive Indication

Acute Kidney Injury [+7]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

Taiwan Province

First Approval Date01 Aug 1961

Clinical Trials associated with Epididymitis

CTR20250612

/ CompletedNot Applicable

盐酸米诺环素胶囊在健康受试者中单中心、随机、开放、单剂量、两制剂、两周期、两序列交叉设计在空腹给药和餐后给药两种状态下人体生物等效性研究

[Translation] A single-center, randomized, open-label, single-dose, two-formulation, two-period, two-sequence crossover design of minocycline hydrochloride capsules in healthy subjects under fasting and fed conditions

本试验旨在研究单次空腹和餐后口服成都瑞尔医药科技有限公司研制、杭州民生药业股份有限公司生产的盐酸米诺环素胶囊（100 mg）的药代动力学特征；以Pfizer Japan Inc.持证、ファイザー株式会社生产的盐酸米诺环素胶囊（MINOMYCIN®/ミノマイシン®，100 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。

[Translation]

This study aimed to study the pharmacokinetic characteristics of minocycline hydrochloride capsules (100 mg) developed by Chengdu Ruier Pharmaceutical Technology Co., Ltd. and produced by Hangzhou Minsheng Pharmaceutical Co., Ltd. after single fasting and postprandial oral administration; minocycline hydrochloride capsules (MINOMYCIN®/ミノマイシン®, 100 mg) certified by Pfizer Japan Inc. and produced by ファイザー Co., Ltd. were used as the reference preparation, and the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared to evaluate the bioequivalence of the two preparations in humans.

Start Date06 Mar 2025

Sponsor / Collaborator

Chengdu Ruier Pharmaceutical Technology Co., Ltd.

CTR20243787

/ CompletedNot Applicable

盐酸米诺环素胶囊在空腹及餐后条件下的人体生物等效性试验

[Translation] Bioequivalence study of minocycline hydrochloride capsules in humans under fasting and fed conditions

考察健康受试者在空腹及餐后条件下，单次口服1粒由杭州和康药业有限公司提供的盐酸米诺环素胶囊【受试制剂T，规格：100mg（按C23H27N3O7计）】与相同条件下单次口服1粒由Pfizer Japan Inc.持证的盐酸米诺环素胶囊【参比制剂R，商品名：MINOMYCIN®，规格：100mg（按C23H27N3O7计）】的药动学特征，评价两制剂的生物等效性及安全性。

[Translation]

To investigate the pharmacokinetic characteristics of a single oral dose of minocycline hydrochloride capsule [test preparation T, strength: 100 mg (calculated as C23H27N3O7)] provided by Hangzhou Hekang Pharmaceutical Co., Ltd. in healthy subjects under fasting and postprandial conditions and a single oral dose of minocycline hydrochloride capsule [reference preparation R, trade name: MINOMYCIN®, strength: 100 mg (calculated as C23H27N3O7)] certified by Pfizer Japan Inc. under the same conditions, and to evaluate the bioequivalence and safety of the two preparations.

Start Date03 Nov 2024

Sponsor / Collaborator

Hangzhou Hekang Pharmaceutical Co., Ltd.

CTR20242860

/ CompletedNot Applicable

法罗培南钠片在健康受试者中的单中心、随机、开放、单剂量、两制剂、两周期、两序列交叉空腹及餐后生物等效性试验

[Translation] A single-center, randomized, open-label, single-dose, two-formulation, two-period, two-sequence crossover fasting and fed bioequivalence study of faropenem sodium tablets in healthy subjects

本试验旨在研究健康受试者单次空腹和餐后口服海南海灵化学制药有限公司研制、生产的法罗培南钠片（200 mg）的药代动力学特征；以Maruho Co., Ltd持证、生产的法罗培南钠片（Farom®，200 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。

[Translation]

This study aimed to investigate the pharmacokinetic characteristics of faropenem sodium tablets (200 mg) developed and produced by Hainan Hailing Chemical Pharmaceutical Co., Ltd. after single fasting and postprandial oral administration in healthy subjects; Faropenem sodium tablets (Farom®, 200 mg) licensed and produced by Maruho Co., Ltd were used as the reference preparation, and the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations were compared to evaluate the bioequivalence of the two preparations in humans.

Start Date02 Sep 2024

Sponsor / Collaborator

Hainan Hailing Chemipharma Corp. Ltd.

100 Clinical Results associated with Epididymitis

100 Translational Medicine associated with Epididymitis

0 Patents (Medical) associated with Epididymitis

2,406

Literatures (Medical) associated with Epididymitis

01 May 2025·Veterinary Microbiology

Pathological and bacteriological investigations of Pasteurella multocida-induced epididymitis in calves

Article

Author: Ikezawa, Mitsutaka ; Tamaboko, Sachi ; Teratani, Chie ; Namba, Kaori ; Yamamoto, Ikumi ; Tanaka, Shogo ; Terao, Aya ; Ueno, Yuichi ; Hashida, Akihiko ; Kimura, Kumiko ; Mizukami, Chiaki ; Kaji, Risa

Between June 2017 and October 2023, five cases of epididymitis caused by Pasteurella multocida were confirmed in four Japanese Black calves and one Japanese Black-Holstein crossbreed calf across five farms in three prefectures in Japan. Although P. multocida is primarily known to cause respiratory diseases in cattle, its role in reproductive disorders, particularly in epididymitis, has not been extensively studied. Histopathological examination showed pyogranulomatous lesions in the epididymal duct and surrounding areas, consisting of ductal extension, immune cell infiltration, epithelial degeneration, abscess formation, and fibrosis with angiogenesis. In the immunohistochemical analysis, positive reactions to anti-P. multocida serotype A antibodies were observed in macrophages and neutrophils in the epididymal ducts and surrounding areas, suggesting an ascending infection rather than hematogenous spread. This report is the first to directly confirm P. multocida involvement in bovine epididymitis through immunohistochemical examination. P. multocida was isolated in pure culture from the scrotal contents in all cases. The isolates were grouped into sequence types ST79 and ST13, commonly found in the respiratory tract and oral cavity of cattle, using the Rural Industries Research and Development Corporation multilocus sequence typing scheme; pulsed-field gel electrophoresis revealed unique band patterns in the isolates from each case. These results suggest that multiple genetically distinct strains, commonly found in the nasal and oral cavities, incidentally infected the epididymis via an ascending route. This bacterium warrants further investigation as a potential cause of reproductive disorders, particularly in Japanese Black cattle.

01 Apr 2025·Rheumatology

De novo manifestations during adalimumab treatment in Behçet’s syndrome

Article

Author: Uygunoglu, Ugur ; Hatemi, Gulen ; Ucar, Didar ; Celik, Aykut Ferhat ; Hamuryudan, Vedat ; Kaymaz, Elif ; Kutlubay, Zekayi ; Hatemi, Ali Ibrahim ; Ugurlu, Serdal ; Melikoglu, Melike ; Sonmez, Ozge ; Fresko, Izzet ; Seyahi, Emire ; Esatoglu, Sinem Nihal ; Ozguler, Yesim

AbstractObjectivesTreatment response may be variable across organ manifestations of Behçet’s syndrome (BS). We aimed to determine the frequency of de novo manifestations during adalimumab treatment.MethodsWe conducted a chart review of all BS patients who received adalimumab in our centre between 2008 and 2023. Demographic data, reasons for initiating adalimumab, concurrent medications, previous treatments, and outcomes were recorded. We defined de novo manifestations as new BS manifestations that occurred for the first time during treatment with adalimumab. For patients with vascular involvement, a new vascular event at another vessel was also considered as a de novo manifestation.ResultsAmong the 335 patients, a de novo manifestation developed in 14 (4%) patients. De novo manifestations were vascular involvement in five patients, arthritis in three, anterior uveitis in two, nervous system involvement in two, gastrointestinal involvement in one, and epididymitis in one patient. The primary reasons for adalimumab treatment were vascular involvement in five patients, uveitis in four, arthritis in three, mucocutaneous involvement in one, and epididymitis in one patient. Upon the development of de novo manifestation, adalimumab was switched to another biologic in four patients, dose was intensified in three, colchicine, conventional immunosuppressives and/or glucocorticoids were added in five, and topical eye drops were added in two patients, leading to remission of de novo manifestations in all patients.ConclusionDe novo manifestations were infrequent (4%) among BS patients treated with adalimumab. Of these, 57% were major organ involvement, mainly vascular involvement. None of the patients developed posterior uveitis.

01 Apr 2025·Radiology Case Reports

All pain, no gain: When epididymitis drops the ball

Article

Author: Phong, Kimberly ; Kampalath, Rony ; Avalos, Lauro Nathaniel ; Giannico, Giovanna

Testicular infarction due to acute epididymitis is a rare but serious complication caused by inflammation that impairs blood flow to the testis. Epididymitis, frequently associated with bacterial infections, usually presents with scrotal pain and swelling, and is commonly managed with a brief course of antibiotics. However, in severe cases, it can progress to ischemia and infarction. This report describes a 46-year-old male with type 2 diabetes who presented with a 1-week history of left testicular pain and swelling. An initial ultrasound confirmed epididymitis, but despite intravenous antibiotic treatment, his symptoms worsened by the second day. Repeat imaging revealed the absence of blood flow, consistent with testicular infarction. This case underscores the importance of timely diagnosis and intervention to prevent such complications.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Epididymitis

Basic Info

Related

Analysis